Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery
1 other identifier
observational
112
0 countries
N/A
Brief Summary
Acute liver failure (ALF) results from an abrupt loss of hepatic metabolic and synthetic function and leads to encephalopathy and potentially multi-organ dysfunction. Aetiologies include autoimmune and metabolic diseases, infectious agents and hepatotoxins. Worldwide, infectious hepatitis (A, B and E) is the most common cause. In Western Europe and the USA, ALF is most frequently caused by paracetamol intoxication. The MBT can produce immediate results to aid in decision making in patients with acute liver disease. Such a test may affect decision-making regarding transplantation in this setting, facilitate appropriate discharge from critical care to other hospital units and to home, provide point of care assessment of therapeutic interventions. The BreathID can potentially help in determining:
- Parameter to include patients in transplant list (the UNOS 1A group)
- Identification that patient deteriorates and needs extended hospitalization/referral to ICU/change in management
- An addition to the MELD and or other scores to estimate risk in other acute patients
- Additional information to that of other commonly utilized prognostic scoring systems The primary end-point of the study is to develop a model to predict deterioration of the liver disease, which incorporates measurements from the MBT along with other potential variables. The data collected will be used to develop a prediction model using data-mining methodology (linear and non-linear regression models, binary trees, neural networks, etc…). The predictive models may include measurements from the MBT, blood test results, as single measurements or as trend over time. The model that will be developed, will attempt to predict the disease deterioration vs. recovery accurately, at an earlier time point than the standard procedure. A threshold will then be determinate based on adequate sensitivity and specificity levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 15, 2011
CompletedFirst Posted
Study publicly available on registry
September 16, 2011
CompletedStudy Start
First participant enrolled
October 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2012
CompletedSeptember 16, 2011
September 1, 2011
1.2 years
September 15, 2011
September 15, 2011
Conditions
Eligibility Criteria
Patients that are hospitalaized.
You may qualify if:
- Adult men or women (\>18 years of age).
- Acute Liver insult
- No evidence of cirrhosis (unless clinical acute Wilsons)
- INR \> 1.5
- Duration of illness \< 24 weeks -
You may not qualify if:
- Patient with any chronic liver disease
- Patient has severe congestive heart failure
- Patient has severe pulmonary hypertension
- Patient has chronic renal insufficiency with severe cardiac disease
- Patient has previous surgical bypass surgery for morbid obesity
- Patient has extensive small bowel resection
- Patient with established extra-hepatic auto-immune disease on long term treatment
- Patient is a recipient of any organ transplant (within the last 3 months)- Patient with proven or suspected hepatocellular carcinoma
- Patient is pregnant
- Patient allergic to paracetamol (such as Tylenol or any other related medications)
- Patients in whom oral intake is contra-indicated
- Patient, based on the opinion of the investigator, should not be enrolled into this study
- Patients or their nominated representative is unwilling to sign informed consent
- Patients that are participating in other clinical trials evaluating experimental treatments or procedures, not including observatory trials -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 15, 2011
First Posted
September 16, 2011
Study Start
October 1, 2011
Primary Completion
December 1, 2012
Last Updated
September 16, 2011
Record last verified: 2011-09